Clinical Update on Cancer: Molecular Oncology of Head and Neck Cancer

Overview

Journal Cell Death Dis

Specialties Cell Biology
General Medicine

Date 2014 Jan 25

PMID 24457962

Citations 97

Authors

Y Suh

I Amelio

T Guerrero Urbano

M Tavassoli

Affiliations

Soon will be listed here.

Abstract

Head and neck cancers encompass a heterogeneous group of tumours that, in general, are biologically aggressive in nature. These cancers remain difficult to treat and treatment can cause severe, long-term side effects. For patients who are not cured by surgery and/or (chemo)radiotherapy, there are few effective treatment options. Targeted therapies and predictive biomarkers are urgently needed in order to improve the management and minimise the treatment toxicity, and to allow selection of patients who are likely to benefit from both nonselective and targeted therapies. This clinical update aims to provide an insight into the current understanding of the molecular pathogenesis of the disease, and explores the novel therapies under development and in clinical trials.

Citing Articles

Carbon nanotubes targeted to the tumor microenvironment inhibit metastasis in a preclinical model of melanoma.

Garcia-Hevia L, Soltani R, Gonzalez J, Chaloin O, Menard-Moyon C, Bianco A Bioact Mater. 2024; 34:237-247.

PMID: 38223536 PMC: 10787223. DOI: 10.1016/j.bioactmat.2023.12.013.

Preclinical Evaluation of the ATR Inhibitor BAY 1895344 as a Radiosensitizer for Head and Neck Squamous Cell Carcinoma.

Odhiambo D, Pittman A, Rickard A, Castillo R, Bassil A, Chen J Int J Radiat Oncol Biol Phys. 2023; 118(5):1315-1327.

PMID: 38104870 PMC: 11294978. DOI: 10.1016/j.ijrobp.2023.12.012.

Lidocaine induces apoptosis in head and neck squamous cell carcinoma through activation of bitter taste receptor T2R14.

Miller Z, Mueller A, Kim T, Jolivert J, Ma R, Muthuswami S Cell Rep. 2023; 42(12):113437.

PMID: 37995679 PMC: 10842818. DOI: 10.1016/j.celrep.2023.113437.

TIPRL1 and its ATM-dependent phosphorylation promote radiotherapy resistance in head and neck cancer.

Cokelaere C, Dok R, Cortesi E, Zhao P, Sablina A, Nuyts S Cell Oncol (Dordr). 2023; 47(3):793-818.

PMID: 37971644 DOI: 10.1007/s13402-023-00895-6.

Inborn Errors of Metabolism with Ataxia: Current and Future Treatment Options.

Bremova-Ertl T, Hofmann J, Stucki J, Vossenkaul A, Gautschi M Cells. 2023; 12(18).

PMID: 37759536 PMC: 10527548. DOI: 10.3390/cells12182314.

References

Yang C, Hung P, Wang P, Liu C, Chu T, Cheng H . miR-181 as a putative biomarker for lymph-node metastasis of oral squamous cell carcinoma. J Oral Pathol Med. 2011; 40(5):397-404. DOI: 10.1111/j.1600-0714.2010.01003.x. View

Kreimer A, Clifford G, Boyle P, Franceschi S . Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev. 2005; 14(2):467-75. DOI: 10.1158/1055-9965.EPI-04-0551. View

Giroglou T, Florin L, Schafer F, Streeck R, Sapp M . Human papillomavirus infection requires cell surface heparan sulfate. J Virol. 2001; 75(3):1565-70. PMC: 114064. DOI: 10.1128/JVI.75.3.1565-1570.2001. View

Begum S, Westra W . Basaloid squamous cell carcinoma of the head and neck is a mixed variant that can be further resolved by HPV status. Am J Surg Pathol. 2008; 32(7):1044-50. DOI: 10.1097/PAS.0b013e31816380ec. View

De Bacco F, Luraghi P, Medico E, Reato G, Girolami F, Perera T . Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer. J Natl Cancer Inst. 2011; 103(8):645-61. DOI: 10.1093/jnci/djr093. View

Warburg O, Wind F, Negelein E . THE METABOLISM OF TUMORS IN THE BODY. J Gen Physiol. 2009; 8(6):519-30. PMC: 2140820. DOI: 10.1085/jgp.8.6.519. View

Walter V, Yin X, Wilkerson M, Cabanski C, Zhao N, Du Y . Molecular subtypes in head and neck cancer exhibit distinct patterns of chromosomal gain and loss of canonical cancer genes. PLoS One. 2013; 8(2):e56823. PMC: 3579892. DOI: 10.1371/journal.pone.0056823. View

Vermorken J, Stohlmacher-Williams J, Davidenko I, Licitra L, Winquist E, Villanueva C . Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. Lancet Oncol. 2013; 14(8):697-710. DOI: 10.1016/S1470-2045(13)70181-5. View

Burtness B, Goldwasser M, Flood W, Mattar B, Forastiere A . Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol. 2005; 23(34):8646-54. DOI: 10.1200/JCO.2005.02.4646. View

10.

Roh J, Kang S, Minn I, Califano J, Sidransky D, Koch W . p53-Reactivating small molecules induce apoptosis and enhance chemotherapeutic cytotoxicity in head and neck squamous cell carcinoma. Oral Oncol. 2010; 47(1):8-15. PMC: 3032831. DOI: 10.1016/j.oraloncology.2010.10.011. View

11.

Loeffler-Ragg J, Witsch-Baumgartner M, Tzankov A, Hilbe W, Schwentner I, Sprinzl G . Low incidence of mutations in EGFR kinase domain in Caucasian patients with head and neck squamous cell carcinoma. Eur J Cancer. 2005; 42(1):109-11. DOI: 10.1016/j.ejca.2005.08.034. View

12.

Brunner T, Kunz-Schughart L, Grosse-Gehling P, Baumann M . Cancer stem cells as a predictive factor in radiotherapy. Semin Radiat Oncol. 2012; 22(2):151-74. DOI: 10.1016/j.semradonc.2011.12.003. View

13.

Wilhelm S, Adnane L, Newell P, Villanueva A, Llovet J, Lynch M . Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther. 2008; 7(10):3129-40. DOI: 10.1158/1535-7163.MCT-08-0013. View

14.

Kreimer A, Johansson M, Waterboer T, Kaaks R, Chang-Claude J, Drogen D . Evaluation of human papillomavirus antibodies and risk of subsequent head and neck cancer. J Clin Oncol. 2013; 31(21):2708-15. PMC: 3709056. DOI: 10.1200/JCO.2012.47.2738. View

15.

Rischin D, Young R, Fisher R, Fox S, Le Q, Peters L . Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol. 2010; 28(27):4142-8. PMC: 2953971. DOI: 10.1200/JCO.2010.29.2904. View

16.

Grandis J, Tweardy D . Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res. 1993; 53(15):3579-84. View

17.

Weng A, Ferrando A, Lee W, Morris 4th J, Silverman L, Sanchez-Irizarry C . Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science. 2004; 306(5694):269-71. DOI: 10.1126/science.1102160. View

18.

Bartel D, Chen C . Micromanagers of gene expression: the potentially widespread influence of metazoan microRNAs. Nat Rev Genet. 2004; 5(5):396-400. DOI: 10.1038/nrg1328. View

19.

Isayeva T, Li Y, Maswahu D, Brandwein-Gensler M . Human papillomavirus in non-oropharyngeal head and neck cancers: a systematic literature review. Head Neck Pathol. 2012; 6 Suppl 1:S104-20. PMC: 3394168. DOI: 10.1007/s12105-012-0368-1. View

20.

Haase V . The VHL tumor suppressor: master regulator of HIF. Curr Pharm Des. 2009; 15(33):3895-903. PMC: 3622710. DOI: 10.2174/138161209789649394. View